Workflow
惠泰医疗(688617) - 2022 Q3 - 季度财报
APTAPT(SH:688617)2022-10-26 16:00

Financial Performance - The company's operating revenue for Q3 2022 was ¥331,669,714.11, representing a year-on-year increase of 58.96%[4] - The net profit attributable to shareholders for Q3 2022 was ¥101,704,287.93, reflecting a significant increase of 115.59% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥92,171,303.60, up 105.31% year-on-year[4] - The basic earnings per share for Q3 2022 was ¥1.53, an increase of 115.49% compared to the same period last year[5] - Total revenue for the first three quarters of 2022 reached ¥887,326,586.93, a significant increase of 49.6% compared to ¥593,394,901.72 in the same period of 2021[20] - Net profit for the first three quarters of 2022 was ¥247,647,452.87, representing a 59.3% increase from ¥155,423,196.22 in the same period of 2021[22] - The net profit attributable to the parent company for the first three quarters of 2022 was approximately ¥260.58 million, an increase of 60.8% compared to ¥162.03 million in the same period of 2021[23] - Basic earnings per share for the first three quarters of 2022 were ¥3.91, up from ¥2.50 in the same period of 2021, reflecting a growth of 56%[24] - Total comprehensive income for the first three quarters of 2022 reached approximately ¥251.54 million, compared to ¥155.42 million in the same period of 2021, marking an increase of 61.8%[23] Research and Development - The total R&D investment for Q3 2022 was ¥45,951,832.90, which is a 49.50% increase year-on-year[5] - Research and development expenses for the first three quarters of 2022 were ¥134,322,322.41, a significant increase of 65.8% from ¥81,026,091.54 in the same period of 2021[22] - The company has increased its investment in new product and technology development, which is expected to drive future growth[9] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date period was ¥279,573,710.23, reflecting a significant increase of 209.24%[5] - Cash inflow from operating activities for the first three quarters of 2022 was approximately ¥1.02 billion, compared to ¥702.61 million in the same period of 2021, representing an increase of 45%[25] - The net cash flow from operating activities for the first three quarters of 2022 was approximately ¥279.57 million, significantly higher than ¥90.41 million in the same period of 2021, indicating a growth of 209%[26] - The company's cash and cash equivalents as of September 30, 2022, amounted to ¥389,175,392.30, an increase from ¥309,660,762.50 as of December 31, 2021[17] - The ending balance of cash and cash equivalents as of September 30, 2022, was approximately ¥389.18 million, compared to ¥124.67 million at the end of the same period in 2021, reflecting a significant increase of 211%[27] Shareholder Information - Total number of common shareholders at the end of the reporting period was 4,506[11] - The largest shareholder, Cheng Zhenghui, holds 16,685,027 shares, representing 25.03% of total shares[11] - There were no significant changes in the status of shares held by major shareholders, with no pledges or freezes reported[11] - The total number of shareholders with voting rights restored for preferred shares was not applicable[11] Liabilities and Equity - Total liabilities increased to ¥447,670,542.76 as of September 30, 2022, compared to ¥222,016,219.03 at the end of 2021, marking a substantial rise of 101.5%[19] - The company reported a total equity of ¥1,687,876,108.45 as of September 30, 2022, down from ¥1,791,065,324.70 at the end of 2021, indicating a decrease of 5.8%[19] Future Outlook - The company plans to continue enhancing product performance and expanding market reach, contributing to revenue growth[9] - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming quarters[22] - The company has not disclosed any significant new strategies or product developments in the current reporting period[15]